Gary Schwartz

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Development of cell-cycle inhibitors for cancer therapy
    M A Dickson
    Department of Medicine, Division of Solid Tumor Oncology, Melanoma and Sarcoma Service, and Laboratory of New Drug Development, Memorial Sloan Kettering Cancer Center, New York, NY, U S A
    Curr Oncol 16:36-43. 2009
  2. ncbi Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model
    Oliver Surriga
    Corresponding Author Gary K Schwartz, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065
    Mol Cancer Ther 12:2817-26. 2013
  3. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
  4. ncbi Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors
    Gary K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
    J Clin Oncol 23:5365-73. 2005
  5. ncbi Measuring tumor response and shape change on CT: esophageal cancer as a paradigm
    L H Schwartz
    Department of Radiology, Biostatistics and Epidemiology and Medicine, Memorial Sloan Kettering Cancer Center, New York, 10021, USA
    Ann Oncol 17:1018-23. 2006
  6. ncbi Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy
    Gary K Schwartz
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4499-508. 2005
  7. pmc Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)
    Gary K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:1956-62. 2009
  8. ncbi Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials
    G K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur J Cancer 35:S9-13. 1999
  9. ncbi Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Anticancer Drugs 15:219-27. 2004
  10. ncbi Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors
    Jeremy Kortmansky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1875-84. 2005

Detail Information

Publications65

  1. pmc Development of cell-cycle inhibitors for cancer therapy
    M A Dickson
    Department of Medicine, Division of Solid Tumor Oncology, Melanoma and Sarcoma Service, and Laboratory of New Drug Development, Memorial Sloan Kettering Cancer Center, New York, NY, U S A
    Curr Oncol 16:36-43. 2009
    ..In hematologic malignancies, reports have shown encouraging single-agent and combination activity. Pharmacodynamic studies show that the dose and schedule of these drugs are crucial to permit maximum therapeutic effect...
  2. ncbi Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model
    Oliver Surriga
    Corresponding Author Gary K Schwartz, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065
    Mol Cancer Ther 12:2817-26. 2013
    ....
  3. pmc Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 14:371-82. 2013
    ....
  4. ncbi Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors
    Gary K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA
    J Clin Oncol 23:5365-73. 2005
    ..LY293111 has antineoplastic activity in a variety of preclinical models. The tolerability and pharmacokinetics of LY293111 administered continuously, by mouth, BID for repeat cycles of 21 days was evaluated...
  5. ncbi Measuring tumor response and shape change on CT: esophageal cancer as a paradigm
    L H Schwartz
    Department of Radiology, Biostatistics and Epidemiology and Medicine, Memorial Sloan Kettering Cancer Center, New York, 10021, USA
    Ann Oncol 17:1018-23. 2006
    ..We evaluated the impact of Response Evaluation Criteria in Solid Tumors (RECIST), World Health Organization (WHO) criteria and tumor shape on response assessment in patients with metastatic esophageal cancer...
  6. ncbi Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy
    Gary K Schwartz
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4499-508. 2005
    ..An understanding of the cell cycle and its relationship to p53 are critical for the successful clinical development of these agents for the treatment of patients with gastrointestinal cancers...
  7. pmc Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114)
    Gary K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 27:1956-62. 2009
    ..Toxicity is also significant. More beneficial and safer regimens are needed...
  8. ncbi Raltitrexed (Tomudex) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials
    G K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur J Cancer 35:S9-13. 1999
    ..In conclusion, preliminary data from these phase I studies indicate that the combination of raltitrexed and 5-FU is well tolerated and has encouraging clinical activity...
  9. ncbi Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer
    Gary K Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Anticancer Drugs 15:219-27. 2004
    ..0 mg/m, with manageable toxicity. This combination shows encouraging activity, and survival appears promising in the pre-treated aCRC patient population. Further clinical trials are warranted...
  10. ncbi Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors
    Jeremy Kortmansky
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 23:1875-84. 2005
    ..We designed a phase I clinical trial of FU in combination with UCN-01...
  11. ncbi Targeting the cell cycle: a new approach to cancer therapy
    Gary K Schwartz
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, New York, NY, USA
    J Clin Oncol 23:9408-21. 2005
    ..An understanding of the cell cycle is critical to understanding how best to clinically develop these agents, both as single agents and in combination with chemotherapy...
  12. ncbi Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
    G K Schwartz
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Section, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 19:1985-92. 2001
    ..Activity in gastric cancer xenografts and in a patient with gastric cancer on the phase I trial led to this phase II study of flavopiridol in patients with metastatic gastric cancer...
  13. ncbi Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
    Gary K Schwartz
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Section, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:2157-70. 2002
    ..We therefore designed a phase I clinical trial of sequential paclitaxel and flavopiridol...
  14. pmc Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
    G K Schwartz
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Br J Cancer 104:1862-8. 2011
    ..This phase I, open-label, first-in-human study determined dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of PD 0332991, an oral cyclin-dependent kinase 4/6 inhibitor with potent anti-proliferative activity in vitro/vivo...
  15. ncbi Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells
    Monica Motwani
    Gastrointestinal Oncology Research Laboratory, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cancer Ther 2:549-55. 2003
    ..Flavopiridol alone had no effect in this tumor model. Thus, flavopiridol, when combined with docetaxel in a sequence-specific manner, may provide a completely new therapeutic approach in the treatment of gastric cancer...
  16. pmc A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol
    Mark A Dickson
    Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Cancer Chemother Pharmacol 66:1113-21. 2010
    ..The cyclin-dependent kinase inhibitor flavopiridol increases irinotecan- and fluorouracil-induced apoptosis. We conducted a phase I trial of FOLFIRI + flavopiridol in patients with advanced solid tumors...
  17. ncbi Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastroph
    Archie N Tse
    Gastrointestinal Oncology Research Laboratory, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 64:6635-44. 2004
    ..Moreover, checkpoint abrogation and subsequent apoptosis induced by UCN-01 do not necessarily correlate with reproductive cell death...
  18. ncbi A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol
    Manish A Shah
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 11:3836-45. 2005
    ..We initiated a phase I trial of the sequential combination of irinotecan followed by flavopiridol to determine the maximal tolerated dose of this combination therapy...
  19. pmc Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer
    William P Tew
    Gynecologic Medical Oncology, Medical Oncology Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 27:366-73. 2009
    ..To determine the maximum tolerated dose (MTD), toxicities, and suitable dose for weekly 1-h paclitaxel combined with weekly cisplatin and irinotecan to treat advanced gastrointestinal malignancies...
  20. ncbi The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells
    Christoph Jung
    Gastrointestinal Oncology Research Laboratory, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 9:6052-61. 2003
    ..In view of this, we elected to evaluate the effect of flavopiridol on potentiating RT-induced apoptosis in the human colon cancer cell line HCT-116 and the gastric cancer cell line MKN-74...
  21. doi The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner
    Grazia Ambrosini
    Laboratory of New Drug Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Res 68:2312-20. 2008
    ..In conclusion, after DNA damage by Topo I poisons, flavopiridol targets homologous recombination through a p53-dependent down-regulation of Rad51, resulting in enhancement of apoptosis...
  22. pmc A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus
    David H Ilson
    Gastrointestinal Oncology Service Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 117:1409-14. 2011
    ..Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in patients with previously treated esophageal cancer...
  23. ncbi The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo
    Jayasree S Nair
    Laboratory of New Drug Development, Department of Medicine, MSKCC, New York, New York, USA
    Clin Cancer Res 15:2022-30. 2009
    ..As the topoisomerase I poison CPT-11 induces a G(2) arrest, a mechanistic understanding of the cell cycle interactions between these agents may prove critical for combination therapy...
  24. pmc Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors
    Dana Rathkopf
    Genitourinary Oncology Service, Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 15:7405-11. 2009
    ..Preclinical data indicate that flavopiridol enhances oxaliplatin- and fluorouracil (5FU)-induced apoptosis in a sequence-dependent manner...
  25. ncbi Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer
    Geoffrey Y Ku
    Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Chemother Pharmacol 62:875-80. 2008
    ..We sought to determine the response rate and toxicity profile of sequential paclitaxel and bryostatin-1, a novel, selective inhibitor of protein kinase C, in patients with advanced esophageal cancer...
  26. ncbi Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy
    Lakshmi Pendyala
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Chemother Pharmacol 51:376-84. 2003
    ..The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m(2)) treatment which followed paclitaxel (175 mg/m(2)) and BNP7787 (8.2 to 27.6 g/m(2))...
  27. ncbi Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome
    Harvey G Moore
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Room C 1077, New York, NY 10021, USA
    Ann Surg Oncol 11:955-61. 2004
    ..Although numerous studies have focused on identifying molecular markers of prognosis in the primary rectal cancer before CMT, our aim was to identify markers of prognosis in residual rectal cancer after preoperative CMT...
  28. ncbi Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor
    Tianhua Guo
    Department of Pathology, Memorial Sloan Kettering Cancer Center, NY 10021, USA
    Clin Cancer Res 13:4874-81. 2007
    ....
  29. pmc Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells
    Grazia Ambrosini
    Laboratory of New Drug Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Mol Cancer Ther 7:890-6. 2008
    ..With growth inhibition at the low nanomolar range, sorafenib, by inhibiting the mitogen-activated protein kinase pathway, may prove to be a novel therapy for patients with MPNST...
  30. ncbi Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes
    Manish A Shah
    Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 11:3296-302. 2005
    ..The clinical evaluation of Drg1 in colorectal cancer has been limited. We performed this study to evaluate the role of Drg1 in a large cohort of patients with metastatic colorectal cancer who were irinotecan naive...
  31. ncbi CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo
    Archie N Tse
    Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 13:591-602. 2007
    ..Chk1 kinase is a critical regulator of both S and G(2)-M phase cell cycle checkpoints in response to DNA damage. This study aimed to evaluate the biochemical, cellular, and antitumor effects of a novel Chk1 inhibitor, CHIR124...
  32. ncbi Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase
    Samuel McNeely
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cell Cycle 9:995-1004. 2010
    ..Additionally, the current study indicates that the combination of Chk1 inhibitor and gemcitabine may be particularly effective in targeting tumors with specific DNA repair defects...
  33. ncbi CDK inhibitors: cell cycle arrest versus apoptosis
    Gary K Schwartz
    Laboratory of New Drug Development and Gastrointestinal Cancers Memorial Sloan Kettering Cancer Center 1275 York Avenue New York, NY 10021, USA
    Cell Cycle 1:122-3. 2002
  34. pmc 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1
    Archie N Tse
    Laboratory of New Drug Development, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Pharmacol 75:124-33. 2009
    ..Taken together, 17AAG specifically inhibits the G(2)/M checkpoint in p53-defective cells by down-regulation of two critical checkpoint kinases, Chk1 and Wee1...
  35. pmc A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors
    Archie N Tse
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 14:6704-11. 2008
    ..We conducted a phase I study of irinotecan and the Hsp90 inhibitor 17AAG, which can also down-regulate Chk1, in patients with solid tumors...
  36. pmc Phase II study of sorafenib in patients with metastatic or recurrent sarcomas
    Robert G Maki
    Melanoma Sarcoma Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Howard 909, New York, NY 10065, USA
    J Clin Oncol 27:3133-40. 2009
    ..Further evaluation of sorafenib in these and possibly other sarcoma subtypes appears warranted, presumably in combination with cytotoxic or kinase-specific agents...
  37. ncbi Cyclin-dependent kinases as targets for cancer therapy
    Manish A Shah
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 21:145-70. 2003
    ..Although phase II evaluation of these combination studies will provide initial evidence of anti-tumor activity, definitive phase III studies will be needed to establish this class of agents in the care of patients with cancer...
  38. ncbi Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway
    Jesse Coward
    Laboratory of New Drug Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Autophagy 5:184-93. 2009
    ..Thus, our studies establish that safingol induces autophagy through inhibition of PKCs and PI3k by safingol directly rather than via changes in endogenous sphingolipids...
  39. ncbi A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers
    Ghassan K Abou-Alfa
    Memorial Sloan Kettering Cancer Center, New York, New York 10022, USA
    Am J Clin Oncol 28:334-9. 2005
    ..A multicenter phase II study to determine the antitumor activity of exatecan was conducted in patients with advanced cholangiocarcinoma and gallbladder carcinoma...
  40. ncbi Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease
    Garrett M Nash
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 9:954-60. 2002
    ..We have reviewed stage IV rectal cancer patients to evaluate the effectiveness of radical surgery without radiation as local therapy...
  41. ncbi Cyclin-dependent kinases as targets for cancer therapy
    Manish A Shah
    Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer Chemother Biol Response Modif 22:135-62. 2005
  42. ncbi Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas
    David R D'Adamo
    Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 23:7135-42. 2005
    ..To evaluate the antitumor activity and tolerability of bevacizumab and doxorubicin in patients with metastatic soft-tissue sarcoma (STS)...
  43. ncbi Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells
    Elliot B Sambol
    Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery and Laboratory of New Drug Development, Department Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Res 66:5858-66. 2006
    ..Our results indicate that targeting KIT expression and these antiapoptotic proteins with flavopiridol represents a novel means to disrupt GIST cell dependence on KIT signaling and collectively renders these cells sensitive to apoptosis...
  44. ncbi Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma
    Manish A Shah
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 24:5201-6. 2006
    ..We evaluated the efficacy and safety of the addition of bevacizumab to chemotherapy in the treatment of gastric and gastroesophageal junction (GEJ) adenocarcinoma...
  45. pmc A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Pancreatology 9:404-9. 2009
    ..This phase II study was designed to further define the efficacy and toxicity of this regimen in patients with previously treated PC...
  46. ncbi A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas
    Robert G Maki
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021 6007, USA
    Cancer 103:1431-8. 2005
    ..Based on evidence of activity in preclinical and Phase I studies, the authors undertook a study of bortezomib, a reversible proteasome inhibitor, for patients with metastatic sarcomas...
  47. ncbi Targeting checkpoint kinase 1 in cancer therapeutics
    Archie N Tse
    Authors Affiliations Gastrointestinal Oncology Service and Melanoma and Sarcoma Service, Division of Solid Tumor Oncology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York
    Clin Cancer Res 13:1955-60. 2007
    ..Further, we discuss the results of recent clinical trials involving the nonspecific checkpoint kinase 1 inhibitor, UCN-01, and the challenges we face with this new therapeutic approach...
  48. ncbi Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma
    Samuel Singer
    Sarcoma Biology Laboratory, Sarcoma Disease Management Program, Department of Surgery, Memorial Sloan Kettering Cancer Center and Genomics Core Facility, Sloan Kettering Institute, New York, NY 10021, USA
    Cancer Res 67:6626-36. 2007
    ..These results support the development of a clinical trial with MDM2 antagonists for liposarcoma subtypes which overexpress MDM2 and show the promise of using this expression dataset for new drug discovery in liposarcoma...
  49. ncbi Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
    Ki Young Chung
    Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, H 816, New York, NY 10021, USA
    J Clin Oncol 23:1803-10. 2005
    ....
  50. pmc A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas
    Igor Matushansky
    Department of Pathology, Herbert Irving Comprehensive Cancer Center, Columbia University, 1130 St Nicholas Avenue, New York, NY 10032, USA
    Am J Pathol 172:1069-80. 2008
    ..Our results indicate that a degree of developmental maturity can be quantitatively assigned to solid tumors, supporting the notion that transformation of a solid tumor stem cell can occur at distinct stages of maturation...
  51. pmc Differentiation-related gene-1 decreases Bim stability by proteasome-mediated degradation
    Grazia Ambrosini
    Department of Medicine, Laboratory of New Drug Development, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 69:6115-21. 2009
    ..Conversely, in the absence of Drg1, Bim was stabilized and bound more abundantly to Hsp70. These results show that Drg1 renders cancer cells more resistant to chemotherapy through enhanced proteasome-mediated Bim degradation...
  52. ncbi Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells
    Monica Motwani
    Gastrointestinal Oncology Research Laboratory, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:3950-5. 2002
    ..Taken together, our data suggest that Drg1 is a novel gene that plays a direct role in resistance to CPT-11. Inhibition of Drg1 may provide a new means to increase the sensitivity of colon cancer cells to CPT-11...
  53. ncbi Treatment of metastatic esophagus and gastric cancer
    Manish A Shah
    Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, the Weil School of Medicine of Cornell University, New York, NY 10021, USA
    Semin Oncol 31:574-87. 2004
    ....
  54. pmc Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780
    Jayasree S Nair
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Biol Cell 20:2218-28. 2009
    ..Thus, we propose for the first time that Aurora B determines cellular fate after an aberrant mitosis by directly regulating the Rb tumor suppressor protein...
  55. pmc gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity
    Raymond D Meng
    Department of Medicine, Division of Solid Tumor Oncology, Laboratory of New Drug Development, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Res 69:573-82. 2009
    ..Therefore, combining GSIs with chemotherapy may represent a novel approach for treating metastatic colon cancers by mitigating the development of chemoresistance...
  56. doi Dietary flaxseed protects against lung ischemia reperfusion injury via inhibition of apoptosis and inflammation in a murine model
    Syed S Razi
    Department of Surgery, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York 10019, USA
    J Surg Res 171:e113-21. 2011
    ..Dietary flaxseed (FS) is a rich source of naturally occurring antioxidants and has been shown to reduce lung IRI in mice. However, the mechanisms underlying the protective effects of FS in IRI remain to be determined...
  57. ncbi A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
    David G Pfister
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Invest New Drugs 20:123-7. 2002
    ..Further investigation is warranted to determine the strength of the correlation between bryostatin-1 activity and PARP cleavage as a surrogate molecular marker of apoptosis...
  58. ncbi Aurora kinases: new targets for cancer therapy
    Richard D Carvajal
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 12:6869-75. 2006
    ....
  59. ncbi Timely airway stenting improves survival in patients with malignant central airway obstruction
    Syed S Razi
    Division of Thoracic Surgery, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, New York, New York, USA
    Ann Thorac Surg 90:1088-93. 2010
    ..Although airway stenting results in significant palliation of symptoms, data regarding improved survival after stenting for advanced thoracic cancer with central airway obstruction are lacking...
  60. ncbi Bryostatin-1: a novel PKC inhibitor in clinical development
    Jeremy Kortmansky
    Department of Medicine, Division of Solid Tumor Oncology, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Invest 21:924-36. 2003
    ..The major toxicities are myalgias, nausea, and vomiting. Although there is minimal single-agent activity, combinations with standard chemotherapy are providing very encouraging results and indicate a new direction in cancer therapy...
  61. pmc IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting
    Mihai Hajdu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Pathol 221:300-7. 2010
    ..Our results confirm LOI in several tumours expressing high levels of IGF2, which may explain the observed paraneoplastic hypoglycaemia...
  62. ncbi Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection
    Brian A Ginsberg
    Ludwig Center for Cancer Immunotherapy, Immunology Program, Sloan Kettering Institute, 1275 York Avenue, New York, NY 10065, USA
    Clin Cancer Res 16:4057-65. 2010
    ..To further define the optimal vaccination strategy, we conducted a pilot clinical trial comparing i.m. injection with particle-mediated epidermal delivery (PMED)...
  63. pmc Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival
    Geoffrey Y Ku
    Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 116:1767-75. 2010
    ..The authors report on advanced refractory melanoma patients treated in a compassionate use trial of ipilimumab at the Memorial Sloan-Kettering Cancer Center...
  64. ncbi Using patients as their own controls for cost evaluation of phase I clinical trials
    Eric J Sherman
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1308-14. 2004
    ..Our objective was to utilize a new approach, using patients as their own controls, to compare in a pilot study the costs of care for patients on phase I trials with those incurred for standard treatment...
  65. doi AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
    Sonya D Zabludoff
    AstraZeneca R and D Boston, 35 Gatehouse Drive, Waltham, MA 02451, USA
    Mol Cancer Ther 7:2955-66. 2008
    ....

Research Grants23

  1. Phase I Trial of Safingol and Cisplatin
    Gary Schwartz; Fiscal Year: 2006
    ..conduct "proof of principle" biological assays to measure the degree of ceramide production and/or S1P inhibition, either of which may be predictive of clinical outcome or toxicity. ..
  2. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2007
    ..Continue to examine the mechanisms by which flavopiridol potentiates CPT-11 induced apoptosis, which should provide the opportunity to identify new biomarkers of response for these flavopiridol drug combinations. ..
  3. MSKCC Clinical Oncology Research Career Development Program
    Gary Schwartz; Fiscal Year: 2007
    ..Conduct cancer therapeutic research in a team setting in which basic and clinical scientists collaborate and interact to expedite the translation of basic research into patient-oriented therapeutic cancer research. ..
  4. Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
    Gary Schwartz; Fiscal Year: 2009
    ..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..
  5. Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc
    Gary Schwartz; Fiscal Year: 2009
    ..Combining new generation drugs that specifically inhibit pathways that promote sarcoma tumor growth (mTOR and IGF- 1R/PI3K/Akt) should result in major advances in the treatment and cure of this disease. ..
  6. Developing New Strategies for Targeting mTOR and IGF-1R/PI3K/Akt Pathways in Sarc
    Gary K Schwartz; Fiscal Year: 2010
    ..Combining new generation drugs that specifically inhibit pathways that promote sarcoma tumor growth (mTOR and IGF- 1R/PI3K/Akt) should result in major advances in the treatment and cure of this disease. ..
  7. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2006
    ..Continue to examine the mechanisms by which flavopiridol potentiates CPT-11 induced apoptosis, which should provide the opportunity to identify new biomarkers of response for these flavopiridol drug combinations. ..
  8. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2005
    ..Continue to examine the mechanisms by which flavopiridol potentiates CPT-11 induced apoptosis, which should provide the opportunity to identify new biomarkers of response for these flavopiridol drug combinations. ..
  9. MENTORING FOR NEW CANCER THERAPEAUTICS
    Gary Schwartz; Fiscal Year: 2005
    ..This K24 award mechanism represents the essence of what we are proposing and for which support is needed. ..
  10. PROTEIN KINASE C--A NOVEL TARGET FOR CANCER THERAPY
    Gary Schwartz; Fiscal Year: 1999
    ..g increase in cdk2 activity); 3) To determine whether a specific PKC isofrom may be a critical target for drug development in induction of apoptosis with chemotherapy by testing PKC antisense for specific isoforms in a laboratory model. ..
  11. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2001
    ..The long-term goal of this phase I study will be to increase the therapeutic benefit of CPT-11 and to identify those patients who would most benefit from the drug combination. ..
  12. PROTEIN KINASE C--A NOVEL TARGET FOR CANCER THERAPY
    Gary Schwartz; Fiscal Year: 2000
    ..g increase in cdk2 activity); 3) To determine whether a specific PKC isofrom may be a critical target for drug development in induction of apoptosis with chemotherapy by testing PKC antisense for specific isoforms in a laboratory model. ..
  13. Drg1: A Novel Molecular Target for Cancer Therapy
    Gary Schwartz; Fiscal Year: 2002
    ..The long-term goal of this phase I study will be to increase the therapeutic benefit of CPT-11 and to identify those patients who would most benefit from the drug combination. ..
  14. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2002
    ..The long-term goal of this phase I study will be to increase the therapeutic benefit of CPT-11 and to identify those patients who would most benefit from the drug combination. ..
  15. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2003
    ..The long-term goal of this phase I study will be to increase the therapeutic benefit of CPT-11 and to identify those patients who would most benefit from the drug combination. ..
  16. CLINICAL TRIALS OF FLAVOPIRIDOL WITH CHEMOTHERAPY
    Gary Schwartz; Fiscal Year: 2004
    ..Continue to examine the mechanisms by which flavopiridol potentiates CPT-11 induced apoptosis, which should provide the opportunity to identify new biomarkers of response for these flavopiridol drug combinations. ..
  17. Phase II Study of Imatinib Mesylate in Patients with Inoperable Melanoma
    Gary K Schwartz; Fiscal Year: 2010
    ..Dose reductions are allowed in the setting of toxicity. Imaging studies will be performed on an every 6 week schedule. ..